Organon & CO 10-Q quarterly reports

Organon & Co. reported Q3 2026 results showing slight revenue decline, progress on the Sun Pharma acquisition, and mixed performance across its product portfolio, with notable growth in Hadlima and Emgality.

Organon & Co. reported a 2% decrease in Q2 2026 sales, impacted by product mix and foreign exchange, while progressing towards its acquisition by Sun Pharma.

Organon & Co. reported a 4% decrease in Q1 2026 revenue to $1.46 billion, impacted by lower sales of key products, while also announcing a significant divestiture and a proposed acquisition.

Organon reported a significant drop in Q3 net income and EPS, alongside a leadership overhaul and internal investigation findings regarding improper Nexplanon sales practices.

Organon & Co. filed an amended quarterly report, revealing an internal investigation found improper sales practices for Nexplanon, leading to management changes and identified material weaknesses in internal controls.

Organon & Co. filed an amended quarterly report disclosing an internal investigation into improper Nexplanon sales practices, leading to management changes and identified material weaknesses in internal controls.

Organon & Co. reported a 26% drop in second-quarter net income to $145 million, driven by lower sales from loss of exclusivity and increased costs, despite strategic acquisitions and debt reduction efforts.

Organon & Co.'s Q1 2025 results reveal a revenue decrease of 7% year-over-year, influenced by foreign exchange rates, loss of exclusivity impacts, and strategic business development activities.

Organon & Co. reported a 4% increase in worldwide sales for the third quarter of 2024, driven by growth in women's health and biosimilars, and a significant increase in net income.

Organon & Co. reports a slight decrease in revenue year-over-year, while making progress in strategic initiatives and debt refinancing.

Organon & Co. saw a 5% increase in revenue in the first quarter of 2024, reaching $1.622 billion, primarily driven by growth in its women's health and biosimilars portfolios.